CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-01 | Loerop James Chief Business Officer | Grant or award · Employee Stock Option (Right to Buy) | +206,500 | 206,500 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Grant or award · Restricted Stock Units | +59,000 | 59,000 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Grant or award · Restricted Stock Units | +147,500 | 147,500 | ||
| 2024-02-01 | Balthaser Kevin Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +206,500 | 206,500 | ||
| 2024-02-01 | Balthaser Kevin Chief Financial Officer | Grant or award · Restricted Stock Units | +59,000 | 59,000 | ||
| 2024-02-01 | Balthaser Kevin Chief Financial Officer | Grant or award · Restricted Stock Units | +147,500 | 147,500 | ||
| 2024-01-01 | Balthaser Kevin Chief Financial Officer | Option exercise | +7,500 | 22,961 | ||
| 2024-01-01 | Balthaser Kevin Chief Financial Officer | Shares withheld for taxes | −2,536 | $1.05 | $3K | 20,425 |
| 2024-01-01 | Balthaser Kevin Chief Financial Officer | Option exercise · Restricted Stock Units | −7,500 | 22,500 | ||
| 2024-01-01 | Manion Douglas J. Pres and CEO | Option exercise | +27,000 | 50,938 | ||
| 2024-01-01 | Manion Douglas J. Pres and CEO | Shares withheld for taxes | −9,125 | $1.05 | $10K | 41,813 |
| 2024-01-01 | Manion Douglas J. Pres and CEO | Option exercise · Restricted Stock Units | −27,000 | 81,000 | ||
| 2023-10-23 | Monahan Joseph Chief Scientific Officer | Sale 10b5-1 | −6,000 | $5.08 | $30K | 129,724 |
| 2023-09-06 | Balthaser Kevin Chief Financial Officer | Purchase | +9,490 | $7.90 | $75K | 15,461 |
| 2023-09-01 | Balthaser Kevin Chief Financial Officer | Option exercise | +1,000 | 6,256 | ||
| 2023-09-01 | Balthaser Kevin Chief Financial Officer | Shares withheld for taxes | −285 | $7.90 | $2K | 5,971 |
| 2023-09-01 | Balthaser Kevin Chief Financial Officer | Option exercise · Restricted Stock Units | −1,000 | 1,000 | ||
| 2023-08-28 | Loerop James Chief Business Officer | Purchase | +14,705 | $6.80 | $100K | 21,688 |
| 2023-08-21 | Monahan Joseph Chief Scientific Officer | Sale 10b5-1 | −6,000 | $7.32 | $44K | 135,724 |
| 2023-08-01 | Manion Douglas J. Pres and CEO | Option exercise | +15,575 | 28,375 |
Page 17 of 34 · 680 trades